Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin as a microbiota-modulating agent in inflammatory bowel disease
2019-004208-37Phase 3Completed
- Sponsor
- UZ Leuven
- Start
- Mar 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of rosuvastatin in autoimmune colitis, Crohn's disease and inflammatory bowel disease (IBD) (2 arms), sponsored by UZ Leuven. Started Mar 2020; status: completed.
02
Drugs
rosuvastatin
03
Conditions
autoimmune colitisCrohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2019-004208-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004208-37.